Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CETAMIDE vs AZO GANTANOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CETAMIDE is an antimicrobial combination of sulfadiazine (a sulfonamide) and trimethoprim. Sulfonamides inhibit dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism.
Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Urinary tract infections,Acute otitis media,Shigellosis,Pneumocystis jirovecii pneumonia,Traveler's diarrhea (off-label)
Urinary tract infections (UTIs) when sulfonamide therapy is indicated (FDA),Pain relief of urinary tract irritation (phenazopyridine component)
500 mg orally every 6 hours; maximum 4 g per day.
AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.
6-8 hours; prolonged (up to 30 hours) in severe renal impairment (Cr Cl <30 m L/min).
Sulfamethoxazole terminal half-life: 9-12 hours in adults with normal renal function (Cr Cl >80 m L/min); prolonged to 20-50 hours in CKD (Cr Cl <30 m L/min); phenazopyridine half-life: 9-11 hours
Sulfadiazine is metabolized via acetylation (N-acetyltransferase) and glucuronidation; trimethoprim is metabolized by oxidative pathways (N-oxidation, N-demethylation) and conjugated with glucuronic acid.
Sulfamethoxazole is primarily metabolized by N-acetylation in the liver (N-acetyltransferase 2); phenazopyridine is metabolized in the liver via glucuronidation and sulfation.
Primarily renal (85-90%) as unchanged drug; biliary/fecal (5-10%).
Renal: 70% as sulfamethoxazole (30% acetylated), N5-acetylated metabolite accounts for 15%; fecal: 20% of dose excreted unchanged in bile; biliary: minor contribution (<5%)
20-25% bound to albumin.
Sulfamethoxazole: 65-70% bound to albumin; phenazopyridine: >99% bound (mainly to albumin)
0.5-0.8 L/kg; indicates distribution into total body water.
Sulfamethoxazole: 0.21-0.28 L/kg (for a 70 kg person: ~15-20 L); phenazopyridine: 4.5-5.5 L/kg (extensive tissue binding, e.g., urinary tract)
Oral: 90-100% (well absorbed).
Oral sulfamethoxazole: 85-95% (well absorbed); phenazopyridine: approximately 90% absorbed
Cr Cl 10-50 m L/min: 250 mg every 6 hours. Cr Cl <10 m L/min: 250 mg every 12 hours.
Sulfamethoxazole/Trimethoprim: Cr Cl >30 m L/min: no adjustment; Cr Cl 15-30 m L/min: reduce standard dose by 50% or extend interval to 24 hours; Cr Cl <15 m L/min: contraindicated. Phenazopyridine: contraindicated in renal impairment.
Child-Pugh Class C: avoid use; Class A or B: no adjustment needed.
Sulfamethoxazole/Trimethoprim: Child-Pugh A: no adjustment; Child-Pugh B: use with caution, no specific dose reduction; Child-Pugh C: contraindicated (risk of hepatotoxicity). Phenazopyridine: cautious use in severe hepatic impairment.
10-15 mg/kg orally every 6 hours; maximum 100 mg/kg/day.
Sulfamethoxazole/Trimethoprim: 6-12 mg/kg/day of trimethoprim component divided every 12 hours; maximum 320 mg trimethoprim/day. Phenazopyridine: not recommended in children <12 years.
Consider dose reduction based on renal function; initial dose not to exceed 2 g per day.
Sulfamethoxazole/Trimethoprim: monitor renal function; reduce dose if Cr Cl <30 m L/min. Increased risk of hyperkalemia and sulfonamide-induced adverse effects. Phenazopyridine: cautious use due to potential renal impairment and CNS effects.
Sulfonamides have been associated with fatal reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, and other blood dyscrasias.
Sulfonamides, including sulfamethoxazole, may cause severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis.
Increased risk of hypersensitivity reactions (SJS, TEN); hematologic toxicity (agranulocytosis, thrombocytopenia); hepatotoxicity; renal toxicity due to crystalluria; hemolytic anemia in G6PD-deficient patients; photosensitivity.
Risk of hypersensitivity reactions including SJS/TEN; blood dyscrasias (agranulocytosis, aplastic anemia); hepatotoxicity; renal impairment; photosensitivity; interference with urine glucose tests.
Hypersensitivity to sulfonamides or trimethoprim; severe hepatic or renal impairment; megaloblastic anemia due to folate deficiency; pregnancy (especially first trimester and near term); lactation; pediatric patients <2 months of age.
Hypersensitivity to sulfonamides or phenazopyridine; porphyria; severe renal impairment (Cr Cl <30 m L/min); G6PD deficiency; infants <2 months; pregnancy at term; lactation.
No significant food interactions known. No dietary restrictions required.
Avoid foods high in vitamin K (e.g., leafy greens) as sulfamethoxazole may potentiate warfarin effects. Maintain adequate fluid intake; dehydration increases crystalluria risk. No specific food avoidance required beyond general hydration.
Pregnancy category C. First trimester: Potential risk of neural tube defects based on animal studies. Second and third trimesters: Increased risk of premature closure of ductus arteriosus and oligohydramnios due to prostaglandin synthesis inhibition. Limited human data; avoid unless benefit outweighs risk.
Phenazopyridine: No adequate studies; animal studies show no fetal harm but not conclusive. Sulfamethoxazole: First trimester – Possible increased risk of neural tube defects; second and third trimesters – Risk of kernicterus in neonate due to bilirubin displacement; avoid near term. Trimethoprim: First trimester – Folate antagonist, increased risk of neural tube defects and cardiovascular anomalies; second and third trimesters – No specific documented risks but theoretical folate antagonism.
Excreted in breast milk in low quantities. M/P ratio not established. Potential risk of adverse effects in nursing infants (e.g., renal dysfunction, bleeding). Use with caution if alternative therapies are not available.
Phenazopyridine: Excreted in breast milk; significance unknown; use caution. Sulfamethoxazole: Excreted in breast milk; M/P ratio ~0.2-0.3; risk of kernicterus in jaundiced or G6PD-deficient infants; avoid in nursing mothers of ill or premature infants. Trimethoprim: Excreted in breast milk; M/P ratio ~0.8-1.0; considered compatible by AAP but monitor infant for folate deficiency.
No standard dosing adjustment during pregnancy. Increased renal clearance and volume of distribution in pregnancy may reduce efficacy; consider dose titration based on clinical response. Avoid in third trimester if possible.
Pregnancy alters pharmacokinetics: Increased renal clearance may reduce sulfamethoxazole and trimethoprim levels; however, no dose adjustment is routinely recommended due to lack of data. Standard doses for urinary tract infection: one tablet (phenazopyridine 200 mg/sulfamethoxazole 400 mg/trimethoprim 80 mg) four times daily. Use lowest effective dose for shortest duration.
Cetamide (sulfacetamide sodium) is a topical ophthalmic sulfonamide used for bacterial conjunctivitis. Monitor for hypersensitivity, as cross-allergy with other sulfonamides may occur. Use with caution in patients with dry eye syndrome or corneal abrasions. Avoid prolonged use to prevent superinfection. Administer with clean hands and do not touch dropper tip to any surface.
AZO GANTANOL combines phenazopyridine (a urinary analgesic) with sulfamethoxazole (a sulfonamide antibiotic). Monitor for sulfonamide hypersensitivity reactions (e.g., Stevens-Johnson syndrome). Phenazopyridine discolors urine orange-red; advise patients to avoid confusion with hematuria. Adjust sulfamethoxazole dose in renal impairment (Cr Cl <30 m L/min contraindicated).
Wash hands before and after applying the eye drops.,Do not touch the dropper tip to your eye or any other surface.,Wait 5 minutes between different eye drops if using more than one type.,Complete the full course of treatment even if symptoms improve.,Do not wear contact lenses during treatment unless directed by your doctor.,Stop use and contact your doctor if you experience rash, itching, or swelling.,Keep the bottle tightly closed when not in use and store at room temperature.
Take with a full glass of water to reduce risk of crystalluria.,Urine may turn orange-red; this is harmless and subsides after stopping the drug.,Complete full course even if symptoms improve; do not skip doses.,Avoid prolonged sun exposure; sulfonamides cause photosensitivity.,Report rash, fever, sore throat, or unusual bruising immediately.
"Sulfacetamide may reduce the efficacy of picosulfuric acid, a stimulant laxative, through antibiotic-mediated disruption of the gut microbiota. The conversion of picosulfate to its active metabolite, BHPM, relies on bacterial azoreductase enzymes in the colon. Sulfacetamide's antibacterial activity against colonic flora can decrease this bioactivation, leading to diminished laxative effect and potential treatment failure for constipation or bowel preparation."
"The risk or severity of adverse effects can be increased when Methenamine is combined with Sulfacetamide."
"The risk or severity of adverse effects can be increased when Sulfacetamide is combined with Mecamylamine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CETAMIDE vs AZO GANTANOL, answered by our medical review team.
CETAMIDE is a Sulfonamide antibiotic that works by CETAMIDE is an antimicrobial combination of sulfadiazine (a sulfonamide) and trimethoprim. Sulfonamides inhibit dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism.. AZO GANTANOL is a Sulfonamide Antibiotic that works by Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CETAMIDE and AZO GANTANOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CETAMIDE is: 500 mg orally every 6 hours; maximum 4 g per day.. The standard adult dose of AZO GANTANOL is: AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CETAMIDE and AZO GANTANOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CETAMIDE is classified as Category C. Pregnancy category C. First trimester: Potential risk of neural tube defects based on animal studies. Second and third trimesters: Increased risk of premature closure of ductus art. AZO GANTANOL is classified as Category C. Phenazopyridine: No adequate studies; animal studies show no fetal harm but not conclusive. Sulfamethoxazole: First trimester – Possible increased risk of neural tube defects; seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.